Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Malignant Solid Tumor × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 167 Myelodysplastic Syndromes 111 Precursor Cell Lymphoblastic Leukemia-Lymphoma 107 Leukemia, Lymphocytic, Chronic, B-Cell 91 Leukemia 90 Lymphoma 78 Lymphoma, Non-Hodgkin 75 Multiple Myeloma 73 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60 Hodgkin Disease 59 Hematologic Neoplasms 59 Recurrence 45 Lymphoma, B-Cell 38 Myeloproliferative Disorders 36 Lymphoma, Mantle-Cell 36 Lymphoma, Follicular 34 Melanoma 31 Lymphoma, Large B-Cell, Diffuse 29 Burkitt Lymphoma 29 Graft vs Host Disease 25 Ovarian Neoplasms 23 Primary Myelofibrosis 22 Lymphoma, B-Cell, Marginal Zone 22 Neoplasms, Plasma Cell 19 Leukemia, Myelomonocytic, Chronic 19 Leukemia, Biphenotypic, Acute 17 Anemia, Refractory, with Excess of Blasts 17 Neuroblastoma 15 Lymphoma, T-Cell 15 Anemia, Aplastic 14

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 2 Colony-Stimulating Factors 2 nabiximols 1 fludarabine 1 camrelizumab 1 Radiofrequency Ablation 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Cyclophosphamide 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03171220 2017-06-06

NRT-01

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡